Pascal Deschatelets Ph.D.
Net Worth

Last updated:

What is Pascal Deschatelets Ph.D. net worth?

The estimated net worth of Dr. Pascal Deschatelets Ph.D. is at least $62,824,945 as of 20 May 2024. He owns shares worth $29,707,467 as insider, has earned $29,071,318 from insider trading and has received compensation worth at least $4,046,160 in Apellis Pharmaceuticals, Inc..

What is the salary of Pascal Deschatelets Ph.D.?

Dr. Pascal Deschatelets Ph.D. salary is $674,360 per year as Co-Founder & Chief Scientific Officer in Apellis Pharmaceuticals, Inc..

How old is Pascal Deschatelets Ph.D.?

Dr. Pascal Deschatelets Ph.D. is 55 years old, born in 1970.

What stocks does Pascal Deschatelets Ph.D. currently own?

As insider, Dr. Pascal Deschatelets Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Apellis Pharmaceuticals, Inc. (APLS) Co-Founder & Chief Scientific Officer 1,115,983 $26.62 $29,707,467

What does Apellis Pharmaceuticals, Inc. do?

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

APLS logo
APLS
Apellis Pharmaceuticals, Inc.
$26.62

Pascal Deschatelets Ph.D. insider trading

Apellis Pharmaceuticals, Inc.

Dr. Pascal Deschatelets Ph.D. has made 37 insider trades between 2019-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 117,206 units of APLS stock on 12 Feb 2020. As of 20 May 2024 he still owns at least 1,115,983 units of APLS stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (Right to Buy) 24,500 $3.76 $92,120
Option
Common Stock 24,500 $3.76 $92,120
Option
Stock Option (Right to Buy) 78,907 $4.31 $340,089
Sale
Common Stock 100 $44.03 $4,403
Sale
Common Stock 22,472 $42.85 $962,903
Sale
Common Stock 56,335 $42.15 $2,374,520
Option
Common Stock 78,907 $4.31 $340,089
Sale
Common Stock 4,728 $54.92 $259,638
Option
Stock Option (Right to Buy) 69,107 $3.76 $259,842
Option
Common Stock 69,107 $3.76 $259,842
Sale
Common Stock 64,379 $54.12 $3,483,998
Sale
Common Stock 100 $63.35 $6,335
Option
Common Stock 69,107 $3.67 $253,623
Option
Stock Option (Right to Buy) 69,107 $3.76 $259,842
Sale
Common Stock 42,750 $61.88 $2,645,156
Sale
Common Stock 26,257 $62.69 $1,646,051
Sale
Common Stock 1,148 $67.77 $77,797
Sale
Common Stock 874 $64.14 $56,057
Sale
Common Stock 3,913 $65 $254,329
Sale
Common Stock 1,632 $66.81 $109,032
Option
Common Stock 18,500 $2.67 $49,395
Sale
Common Stock 12,000 $23.66 $283,920
Option
Stock Option (Right to Buy) 18,500 $2.67 $49,395
Option
Common Stock 18,500 $2.67 $49,395
Sale
Common Stock 12,000 $84.55 $1,014,600
Option
Stock Option (Right to Buy) 18,500 $2.67 $49,395
Sale
Common Stock 12,000 $91.35 $1,096,200
Option
Stock Option (Right to Buy) 18,500 $2.67 $49,395
Option
Common Stock 18,500 $2.67 $49,395
Option
Stock Option (Right to Buy) 18,500 $2.67 $49,395
Option
Common Stock 18,500 $2.67 $49,395
Sale
Common Stock 12,000 $92.39 $1,108,680
Sale
Common Stock 12,000 $78.21 $938,520
Option
Stock Option (Right to Buy) 18,500 $2.67 $49,395
Option
Common Stock 18,500 $2.67 $49,395
Option
Common Stock 18,500 $2.67 $49,395
Sale
Common Stock 12,000 $63.79 $765,480
Option
Stock Option (Right to Buy) 18,500 $2.67 $49,395
Option
Common Stock 18,500 $2.67 $49,395
Sale
Common Stock 12,000 $54.45 $653,400
Option
Stock Option (Right to Buy) 18,500 $2.67 $49,395
Option
Stock Option (Right to Buy) 18,500 $2.67 $49,395
Option
Common Stock 18,500 $2.67 $49,395
Sale
Common Stock 12,000 $46.08 $552,960
Option
Stock Option (Right to Buy) 7,000 $3.67 $25,690
Option
Common Stock 7,000 $3.67 $25,690
Option
Stock Option (Right to Buy) 18,500 $2.67 $49,395
Sale
Common Stock 12,000 $47.5 $570,000
Option
Common Stock 18,500 $2.67 $49,395
Option
Common Stock 18,500 $2.67 $49,395
Sale
Common Stock 12,000 $46.47 $557,640
Option
Stock Option (Right to Buy) 18,500 $2.67 $49,395
Sale
Common Stock 12,000 $57.5 $690,000
Option
Common Stock 18,500 $2.67 $49,395
Option
Stock Option (Right to Buy) 18,500 $2.67 $49,395
Option
Stock Option (Right to Buy) 18,500 $2.67 $49,395
Sale
Common Stock 12,000 $63.98 $767,760
Option
Common Stock 18,500 $2.67 $49,395
Option
Common Stock 18,500 $2.67 $49,395
Option
Stock Option (Right to Buy) 18,500 $2.67 $49,395
Sale
Common Stock 12,000 $62.5 $750,000
Option
Stock Option (Right to Buy) 12,000 $2.67 $32,040
Option
Common Stock 12,000 $2.67 $32,040
Option
Common Stock 6,500 $2.67 $17,355
Sale
Common Stock 12,000 $47.95 $575,400
Option
Stock Option (Right to Buy) 6,500 $2.67 $17,355
Option
Stock Option (Right to Buy) 33,005 $2.67 $88,123
Option
Common Stock 33,005 $2.67 $88,123
Option
Common Stock 6,500 $2.67 $17,355
Option
Stock Option (Right to Buy) 6,500 $2.67 $17,355
Option
Stock Option (Right to Buy) 12,000 $2.67 $32,040
Option
Common Stock 12,000 $2.67 $32,040
Sale
Common Stock 12,000 $44.09 $529,080
Sale
Common Stock 4,000 $44.43 $177,720
Option
Stock Option (Right to Buy) 4,000 $2.67 $10,680
Option
Common Stock 4,000 $2.67 $10,680
Option
Common Stock 6,250 $2.67 $16,688
Option
Stock Option (Right to Buy) 6,250 $2.67 $16,688
Sale
Common Stock 6,250 $2.67 $16,688
Sale
Common Stock 6,250 $2.67 $16,688
Option
Stock Option (Right to Buy) 6,250 $2.67 $16,688
Option
Common Stock 6,250 $2.67 $16,688
Option
Stock Option (Right to Buy) 4,500 N/A N/A
Option
Common Stock 4,500 N/A N/A
Option
Common Stock 6,250 N/A N/A
Option
Stock Option (Right to Buy) 6,250 N/A N/A
Sale
Common Stock 6,250 N/A N/A
Option
Stock Option (Right to Buy) 6,250 $2.67 $16,688
Sale
Common Stock 6,250 $2.67 $16,688
Option
Common Stock 6,250 $2.67 $16,688
Sale
Common Stock 55,398 $40.98 $2,270,155
Option
Common Stock 117,205 $2.14 $250,819
Option
Stock Option (Right to Buy) 117,205 $2.14 $250,819
Option
Stock Option (Right to Buy) 117,206 $2.14 $250,821
Option
Common Stock 117,206 $2.14 $250,821
Sale
Common Stock 52,075 $42.8 $2,228,966
Sale
Common Stock 21,541 $25.44 $548,003
Sale
Common Stock 21,602 $24.76 $534,866
Sale
Common Stock 20,858 $25.3 $527,687

Apellis Pharmaceuticals key executives

Apellis Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: